Depomed (DEPO -6.3%) slides after missing top and bottom line estimates. Sales of Gralise came...

|About: Depomed Inc. (DEPO)|By:, SA News Editor

Depomed (DEPO -6.3%) slides after missing top and bottom line estimates. Sales of Gralise came in at $6.1M as prescription growth for the shingles pain medication fell to 7% during the period. Meanwhile, sales of Zipsor fell to $3M from $4.9M in the previous two quarters. Sales of both products were affected by price increases and wholesaler inventory reductions. SA contributor and analyst Jason Napodano (who was on the CC) calls the stock "cheap" in a comprehensive rundown of the quarter. (PR)